• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Oatmeal Health Unveils AI Diagnostic Platform for Lung Cancer Screening in Underserved FQHC Communities

by Fred Pennic 01/31/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Oatmeal Health, an innovator in AI-driven cancer screening launches its AI-powered radiology risk stratification platform for lung cancer. 

– The solution provides a fully reimbursable second-opinion diagnostic tool covered by Medicare, making it more accessible and affordable for healthcare providers and patients.

AI-Powered Lung Nodule Analysis

Lung cancer remains a leading cause of cancer-related deaths worldwide, but screening rates remain alarmingly low. Oatmeal Health’s platform aims to address this challenge by leveraging AI to enhance the accuracy and efficiency of lung cancer screening, particularly in underserved communities.

Oatmeal Health’s platform utilizes cutting-edge AI and computer vision to analyze 3D low-dose CT scans, automatically detecting, analyzing, and categorizing lung nodules based on their risk profile. This technology streamlines workflows, reduces diagnostic errors, and empowers healthcare providers with actionable insights to support timely interventions.

How It Works

  1. Data Ingestion: The platform ingests CT scan data, identifies regions of interest, and encodes nodule-level and scan-level features.
  2. Deep Learning Analysis: Data is processed through Oatmeal Health’s proprietary deep learning framework, featuring convolutional neural networks (CNNs) optimized for 3D imaging.
  3. Risk Stratification: Advanced computer-aided detection (CADe) and diagnosis (CADx) methodologies ensure accurate risk stratification, complementing established protocols like Lung-RADS.

Trained on a diverse dataset of over 100,000 CT scans, Oatmeal Health’s platform boasts exceptional accuracy, with an AUROC of 0.94, validating its reliability in real-world clinical settings.

Driving Positive Change in Lung Cancer Care

Oatmeal Health’s platform has demonstrated significant success in pilot programs, achieving a 90% patient conversion rate for telemedicine-based shared decision-making visits. The company is actively engaging with healthcare providers, payers, and policymakers to accelerate AI adoption and improve lung cancer outcomes.

“Our mission is clear: to democratize access to life-saving cancer screening technologies, particularly in communities that need it most,” said Jonathan Govette, CEO of Oatmeal Health. “By leveraging AI and focusing on underserved populations, we’re not just improving screening rates—we’re saving lives and setting a new standard for equitable healthcare.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Cancer Detection, Cancer Diagnostics, Lung Cancer, Oncology, Oncology Platform

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |